Eventide Asset Management EVH Position
Exited4-Fund ConvergenceEventide Asset Management exited their position in Evolent Health, Inc. (EVH) in Q4 2025, after holding the stock for 12 quarters.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
EVH is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 16.5% of float with 5.1 days to cover, indicating significant bearish positioning against the stock.
About Evolent Health, Inc.
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
Full company profile →Short Interest
16.5%
5.1 days to cover
Eventide Asset Management EVH Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Exited | 0 | -6,292,511 | $0 |
| Q3 2025 | Increased | 6,292,511 | +2,205,659 | $53.2M |
| Q2 2025 | Decreased | 4,086,852 | -1,990,339 | $46.0M |
| Q1 2025 | Increased | 6,077,191 | +1,524,885 | $57.6M |
| Q4 2024 | Increased | 4,552,306 | +748,202 | $51.2M |
| Q3 2024 | Increased | 3,804,104 | +64,985 | $107.6M |
| Q2 2024 | Increased | 3,739,119 | +1,096,551 | $71.5M |
| Q1 2024 | Increased | 2,642,568 | +3,622 | $86.7M |
| Q4 2023 | Increased | 2,638,946 | +6 | $87.2M |
| Q3 2023 | Increased | 2,638,940 | +796 | $71.9M |
| Q2 2023 | Increased | 2,638,144 | +735,389 | $79.9M |
| Q1 2023 | New | 1,902,755 | +1,902,755 | $61.7M |
Frequently Asked Questions
Does Eventide Asset Management own EVH?
No. Eventide Asset Management exited their position in Evolent Health, Inc. (EVH) in Q4 2025. They previously held the stock for 12 quarters.
How many hedge funds own EVH?
4 specialist biotech hedge funds currently hold EVH, including RA Capital Management, Rock Springs Capital, OrbiMed Advisors and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy EVH?
Eventide Asset Management's position in EVH was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's EVH position increasing or decreasing?
Eventide Asset Management completely exited their EVH position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
EVHCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →